Biohaven's Opakalim Triples Seizure Control; Two More Drugs Advance to Pivotal Trials with Strong Data
BHVN sits 48% above its 52-week low of $7.48 on elevated volume (2.2× avg).
Summary
Biohaven reported strong clinical data for its epilepsy drug Opakalim, which tripled the median time to a second generalized tonic-clonic seizure in a proof-of-concept trial. Additionally, two other pipeline assets, BHV-1300 for Graves' disease and BHV-1400 for IgA nephropathy, demonstrated significant biomarker reductions. This positive news, which follows an 8-K filing today, is highly material as it validates multiple programs and sets BHV-1300 and BHV-1400 up for pivotal Phase 3 trials starting mid-2026. The successful progression of these drugs significantly de-risks the company's future revenue potential. Investors will be watching for the initiation of these Phase 3 trials in mid-2026.
At the time of this announcement, BHVN was trading at $11.07 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $7.48 to $18.57. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.